What is AbbVie's elahere — net revenues?

AbbVie (ABBV) reported elahere — net revenues of $198M in Q1 2026.

How has AbbVie's elahere — net revenues changed year-over-year?

AbbVie's elahere — net revenues increased by 10.6% year-over-year, from $179M to $198M.

What does elahere — net revenues mean?

This metric represents the total gross sales of the Elahere product line minus returns, allowances, and rebates. It serves as a key indicator of the commercial adoption and market penetration of this specific oncology therapeutic within the company's broader portfolio. Monitoring these revenues helps investors assess the growth trajectory and competitive positioning of the drug in the ovarian cancer treatment market.

AbbVie ABBV Elahere — Net revenues

Other product segments

Skyrizi

$4.48B+30.9%

Rinvoq

$2.12B+23.3%

All other

$1.03B-18.2%

Botox Therapeutic

$1.01B+16.5%

Vraylar

$905M+18.3%

Venclexta

$770M+15.8%

Humira

$688M-38.6%

Botox Cosmetic

$668M+20.1%

Imbruvica

$556M-24.7%

Mavyret

$351M+14.7%

Ubrelvy

$339M+41.3%

Qulipta

$296M+53.4%

Other Aesthetics

$286M-9.2%

Linzess

$283M+91.2%

Juvederm Collection

$232M+0.4%

Vyalev

$201M+219%

Other Neuroscience

$125M-19.4%

Epkinly

$83M+62.7%

Similar metrics at other companies

REGNEYLEA — Revenue

$412.2M-45.4%

SUPNQelbree — Total revenues

$77.84M+20.2%

JNJERLEADA — Sales to customers (Note 9)

$995M+9.6%

EOLSProduct revenue, net — Total net revenues

$72.75M+6.9%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

AMRXHormonal / allergy — Net revenue

$35.93M+5.1%

Other financials

Income statement

See full

Revenue$15.0B+12.4%

Gross profit$10.8B+15.4%

Operating income$4.0B+6.9%

Net income$695.0M-46.0%

EPS (diluted)$0.39-45.8%

Balance sheet

See full

Cash & equivalents$9.4B+81.5%

Total debt$62.4B+1.8%

Total equity-$6.7B-569%

Total assets$136.46B+0.2%

Cash flow

See full

Operating cash flow$3.8B+134%

CapEx$265.0M+12.8%

Free cash flow$3.6B+155%

Valuation

See full

Market cap$465.02B+39.1%

P/E127.9×+39.1×

P/S7.4×+1.7×

Profitability

See full

Gross margin70.7%0.0pp

Operating margin24.4%—

Net margin5.8%-1.5pp

FCF margin31.8%+5.0pp

Returns & leverage

See full

Return on equity89%+32.7pp

Debt / equity46.6×+38.6×

Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's elahere — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbbVie's elahere — net revenues?: AbbVie (ABBV) reported elahere — net revenues of $198M in Q1 2026.
How has AbbVie's elahere — net revenues changed year-over-year?: AbbVie's elahere — net revenues increased by 10.6% year-over-year, from $179M to $198M.
What does elahere — net revenues mean?: This metric represents the total gross sales of the Elahere product line minus returns, allowances, and rebates. It serves as a key indicator of the commercial adoption and market penetration of this specific oncology therapeutic within the company's broader portfolio. Monitoring these revenues helps investors assess the growth trajectory and competitive positioning of the drug in the ovarian cancer treatment market.